The Myc/Max/Mad network of transcription factors regulates cell proliferation, differentiation, and transformation. Similar to other proteins of the network, Mnt forms heterodimers with Max and binds CACGTG E-Box elements. Transcriptional repression by Mnt is mediated through association with mSin3, and deletion of the mSin3-interacting domain (SID) converts Mnt to a transcriptional activator. Mnt is coexpressed with Myc in proliferating cells and has been suggested to be a modulator of Myc function. We report that Mnt is expressed both in growth-arrested and proliferating mouse fibroblasts and is phosphorylated when resting cells are induced to re-enter the cell cycle. Importantly, the interaction between Mnt and mSin3 is disrupted upon serum stimulation resulting in decreased Mnt-associated HDAC activity. Furthermore, we demonstrate that Mnt binds and recruits mSin3 to the Myc target gene cyclin D2 in quiescent mouse fibroblasts. Interference with Mnt expression by RNAi resulted in upregulation of cyclin D2 expression in growth-arrested fibroblasts, supporting the view that Mnt represses cyclin D2 transcription in quiescent cells. Our data suggest a model in which phosphorylation of Mnt at cell cycle entry results in disruption of Mnt-mSin3-HDAC1 interaction, which allows induction of Myc target genes by release of Mntmediated transcriptional repression. Oncogene (2005) 24, 8326-8337.
Introduction
The Myc/Max/Mad network proteins are transcription factors that belong to the basic-helix-loop-helix-leucine-zipper (bHLHZip) family and act as key regulators of cell proliferation, differentiation, and apoptosis (Henriksson and Lu¨scher, 1996; Grandori et al., 2000; Oster et al., 2002) . Myc genes are deregulated in many human and animal tumors of diverse types (Cole, 1986) . The Myc proteins bind DNA and activate transcription when associated with Max (Amati et al., 1992; Kretzner et al., 1992) . In addition, Max also forms heterodimers with Mad family proteins, Mnt and Mga (Ayer and Eisenman, 1993; Zervos et al., 1993; Hurlin et al., 1995 Hurlin et al., , 1997a Hurlin et al., , 1999 Meroni et al., 1997) . All Max heterodimers bind to a short DNA sequence with the consensus motif CA(C/T)GTG, called E-Box element. Unlike other Myc network proteins, Max is also able to form DNAbinding homodimers in vivo .
Myc proteins are expressed primarily in proliferating cells and are usually downregulated upon cell differentiation (Henriksson and Lu¨scher, 1996; Oster et al., 2002) . In response to signals from the environment, Myc promotes cell cycle progression and cell growth, blocks differentiation, potentiates apoptosis, stimulates genomic instability, drives transformation, and activates angiogenesis (Henriksson and Lu¨scher, 1996; Grandori et al., 2000; Oster et al., 2002) . It is believed that Myc carries out all these biological activities by transcriptional regulation. Myc has been shown to activate a number of cellular target genes and using chromatin immunoprecipitation it has been demonstrated that Myc physically binds to several of these promoters in vivo (Eberhardy et al., 2000; Fernandez et al., 2003; O'Connell et al., 2003; Orian et al., 2003; Mao et al., 2003) . Transcriptional activation by Myc is achieved by recruitment of histone acetyltransferases (HATs) to target promoters, which induces chromatin relaxation and allows transcription (McMahon et al., 1998; Park et al., 2001) . In addition, Myc has the ability to repress transcription by association with the Miz-1 protein at DNA sequences called initiator elements (Staller et al., 2001; Wanzel et al., 2003) .
The Mad family proteins, in contrast to Myc, are expressed mainly in differentiating cells and mediate transcriptional repression (Ayer and Eisenman, 1993; Zervos et al., 1993; Larsson et al., 1994; Hurlin et al., 1995; Que´va et al., 1998) . They are short lived and their expression varies in different tissues. In some cell lines, Mad proteins are expressed sequentially during the differentiation process (Que´va et al., 1998) . It has been suggested that their function is to induce cell cycle arrest, which is required for the subsequent induction of specific programs of gene expression resulting in differentiation (Grandori et al., 2000) . All Mad family members share a common region called the Sin3-interaction domain (SID) that mediates association with mSin3A and mSin3B, which in turn recruit histone deacetylases (HDACs) and corepressor molecules Schreiber-Agus et al., 1995; Hassig et al., 1997; Laherty et al., 1997; Sommer et al., 1997) . Removal of acetyl groups from histones is believed to bring the chromatin to a more condensed state, inaccessible to the transcription machinery (Wolffe, 1997) . However, the ability of Mad1 to repress transcription does not depend solely on the SID since deletion of a carboxy-terminal region was shown to abolish transcriptional repression and abrogate the ability of Mad to reverse an Myc-imposed differentiation block (Barrera-Hernandez et al., 2000) .
In contrast to the Myc and Mad genes, another member of the Myc/Max/Mad network, Mnt, is expressed both in proliferating and differentiating cells in all tissues tested, although at different levels (Hurlin et al., 1997a; Meroni et al., 1997) . Mnt is a short-lived nuclear protein with a half-life of 30-45 min. As a heterodimer with Max, Mnt inhibits Myc-induced cellular transformation and Myc-dependent activation of promoters containing E-Box elements (Hurlin et al., 1997a, b) . Like Mad proteins, Mnt possesses an SID that mediates transcriptional repression (Hurlin et al., 1997a; Meroni et al., 1997) . Moreover, deletion of the SID turns Mnt into a transcriptional activator. This effect may be associated with the proline-rich regions of Mnt, which resembles the activation domains of other transcription factors (e.g., Box I of c-Myc) (Hurlin et al., 1997a) . It is therefore possible that the ability of Mnt to repress or activate transcription might be regulated. Such regulation could involve alternative splicing, posttranslational modifications, protein interactions, or yet other mechanisms. Since both Myc and Mnt are expressed simultaneously and bind the same DNA sequences, albeit with different outcome, Mnt has been suggested to modulate the transcriptional activation function of Myc.
In a recent study, Mnt knockout mice were generated and characterized. These mice exhibited defective embryonic growth, craniofacial defects and died within several days after birth . Fibroblasts derived from Mnt-null mouse embryos displayed several features characteristic of Myc-overexpressing fibroblasts; including faster growth, increased sensitivity to apoptosis-inducers, escape from senescence, and susceptibility to transformation by oncogenic Ras alone (Hurlin et al., 2003) . This phenotype could be reproduced in cells stably expressing Mnt-targeting siRNA . These studies demonstrated a strong connection between Myc and Mnt, supporting the notion that Mnt may serve as a modulator of Myc function . In addition, it is interesting to note that dMnt is the sole Drosophila homolog of the mammalian Mnt and Mad family of transcriptional repressors (Peyrefitte et al., 2001; Orian et al., 2003) .
We have previously analysed the DNA binding of Myc family proteins during differentiation of human promyelocytic leukemia HL60 cells (Xu et al., 2001) . We found that Mnt/Max was the most abundant Maxcontaining E-box-binding complex in quiescent cells and were therefore interested in further characterization of Mnt. In particular, we wanted to analyse whether transcriptional repression by Mnt was regulated. We found that Mnt is phosphorylated in vivo when resting cells are induced to re-enter into the cell cycle. Importantly, we demonstrate that Mnt interacts with mSin3 under physiological conditions, and that the Mnt-mSin3 interaction is disrupted, resulting in decreased Mnt-associated HDAC activity, when quiescent cells are stimulated with serum. Our data also indicate that transcriptional repression by Mnt is negatively regulated by phosphorylation, which in turn may allow for activation of Myc target genes.
Results

Mnt is expressed throughout the cell cycle in immortalized mouse fibroblasts
It was previously shown that Mnt is expressed both in quiescent and proliferating cells (Hurlin et al., 1997a; Meroni et al., 1997) . To study Mnt expression during cell cycle progression, NIH3T3 mouse fibroblasts were synchronized by serum depletion for 48 h. The cells were induced to enter the cell cycle by addition of 10% serum and were then harvested every 5 h. Cell synchronization was confirmed by FACS analysis of propidium iodine (PI)-stained cells (Figure 1a) . Mnt was present at all time points analysed as shown by Western blot (Figure 1b) . Consistent with earlier observations, we found that Mnt migrated as a doublet of 72 and 74 kDa in proliferating cells (Hurlin et al., 1997a; Meroni et al., 1997) . However, in growth-arrested cells the faster migrating 72 kDa form was predominant, whereas the slower migrating 74 kDa form was prevalent in serumstimulated cells (Figure 1b) . We also evaluated Myc protein expression upon serum stimulation. As expected, Myc was transiently induced after serum addition, and was expressed at basal levels thereafter (Figure 1b ). These observations are in agreement with previous studies (Hurlin et al., 1997a; Meroni et al., 1997) and suggest that Mnt is coexpressed with Myc in proliferating cells.
Next, we analysed the DNA binding of Mnt/Max complexes by electrophoretic mobility shift assay (EMSA). We found that Mnt/Max bound to the consensus E-Box both in quiescent cells and after mitogenic stimulation (Figure 1c ). USF and Mnt/Max were the most prominent E-box binding complexes in mouse fibroblasts. These data suggest that Mnt is expressed and possesses DNA-binding activity throughout cell cycle progression.
Mnt is a phosphoprotein
It has previously been suggested that the 74-kDa species of Mnt is derived from the 72-kDa form of the protein (Hurlin et al., 1997a) . To address whether the slower migrating protein represented the hyperphosphorylated form of Mnt, we treated whole-cell extracts from proliferating NIH3T3 cells with lambda protein phosphatase (lPPase). Phosphatase treatment resulted in disappearance of the slower migrating form of the protein (Figure 2a, upper panel) . Dephosphorylation was inhibited by the specific phosphatase inhibitor sodium orthovanadate (Na 3 VO 4 ). Similarly, lPPase treatment of Mnt immunoprecipitates eliminated the slower migrating band (Figure 2a, lower panel) . These observations suggest that the 74 kDa species of Mnt represents the hyperphosphorylated form of the protein.
To further confirm that Mnt is post-translationally modified by phosphorylation, we performed in vivo phosphate-labeling assays and immunoprecipitated Mnt from NIH3T3 and TGR-1 fibroblasts. We found that the Mnt antibody precipitated phosphorylated Mnt from asynchronously growing NIH3T3 and TGR-1 cells ( Figure 2b and data not shown). Stimulation of quiescent fibroblasts with serum significantly increased Mnt phosphorylation (Figure 2b and data not shown). These results verified that Mnt indeed is a phosphoprotein in vivo.
Next, we were interested in the nature of the kinase(s) that phosphorylate(s) Mnt. We therefore performed a time course experiment and found that Mnt is phosphorylated already 10 min after serum stimulation of quiescent cells (Figure 2c ). This prompted us to stimulate quiescent fibroblasts with serum in the presence the MKK/ERK signal transduction pathway inhibitor U0126. Our analysis showed that treatment with U0126 resulted in inhibition of Mnt phosphorylation after serum stimulation (Figure 2d ), suggesting that kinases in the MKK/ERK pathway are potential candidates for phosphorylation of Mnt.
We also analysed whether phosphatase treatment would influence Mnt/Max DNA binding and found that treatment with lPPase resulted in a slower mobility of the Mnt/Max as well as of the Max/Max complex in EMSA (Figure 2e) . Thus, the Mnt/Max mobility shift could be due to either a change in the phosphorylation status of Mnt, Max, or of both proteins. Addition of the phosphate inhibitor Na 3 VO 4 prevented the mobility shifts (Figure 2e ).
Binding of Mnt to mSin3 is inhibited at re-entry into the cell cycle Given the fact that the SID has been shown to be crucial for transcriptional repression by Mnt, we analysed whether we could observe recruitment of mSin3 to Mnt in cell extracts. To this end we performed immunoprecipitaion experiments followed by Western blot analysis in NIH3T3 cells and demonstrated that mSin3B is co-immunoprecipitated with Mnt ( Figure 3a ). Control immunoprecipitations with normal rabbit IgG, mSin3B, and HDAC1 showed that Mnt and HDAC1 antibodies precipitated similar amounts of mSin3 Figure 1 Mnt is expressed and binds DNA in quiescent and proliferating mouse fibroblasts. NIH3T3 cells were starved in 0.1% FBS for 48 h. After addition of 10% serum, cells were collected every 5 h and analysed for cell cycle distribution by FACS (a), for expression of Mnt and Myc by Western blotting (WB) (b), and for DNA binding by EMSA using the consensus (CACGTG) E-Box element (c). The USF and Mnt/Max complexes are indicated to the left in the EMSA. Antibodies against Mnt, Max, and USF were used to identify DNA-binding complexes protein ( Figure 3a) . Next, we investigated whether the ability of Mnt to recruit mSin3 was subject to regulation. To analyse the association of Mnt and mSin3 during cell cycle progression, serum-starved NIH3T3 cells were stimulated with 10% serum and harvested every 5 h. Cell extracts were used for immunoprecipitations with a-Mnt polyclonal antibody and separated on SDS-polyacrylamide gels followed by Western blotting. Incubation with a-mSin3A and amSin3B revealed that Mnt interacted with mSin3 proteins during quiescence and in cells that had entered S phase following addition of serum (Figure 3b ). However, 5 and 10 h after serum stimulation, when the cells re-enter into the cell cycle, the interaction between Mnt and mSin3 proteins was almost undetectable (Figure 3b ). This was not due to differences in expression since the total levels of mSin3 proteins did not vary significantly during cell cycle progression ( Figure 3b ). As Mnt was present mainly in the 72 kDa, hypophosphorylated form in the immunoprecipitates from quiescent cells, these data suggest that interaction with mSin3 proteins was mediated by the faster migrating form of Mnt. Conversely, the hyperphosphorylated form of Mnt, which appeared concomitant with serum stimulation, may interact less efficiently. These results raise the possibility that phosphorylation of Mnt may disrupt the Mnt-mSin3 interaction at reentry into the cell cycle.
Since we had observed that the MKK/ERK signal transduction pathway inhibitor U0126 inhibited phosphorylation of Mnt upon serum stimulation, we investigated its influence on Mnt-mSin3 interaction. NIH3T3 cells were starved for 48 h and stimulated with serum in the presence or absence of U0126. Western blotting revealed that no change in the expression pattern of Mnt and mSin3B occurred. In contrast, the interaction between Mnt and mSin3B was disrupted after serum stimulation but was restored upon U0126 treatment (Figure 3c ), suggesting that phosphorylation of Mnt by kinases in the MKK/ERK pathway results in displacement of mSin3 from Mnt. Asynchronously growing NIH3T3 cells were incubated with or without lPPase in the presence or absence of Na 3 VO 4 and analysed by EMSA (e). The Mnt/Max* and Max/Max* complexes with novel mobilities that appeared upon lPPase treatment are shown to the right Mnt recruits mSin3 to the cyclin D2 promoter in quiescent NIH3T3 fibroblasts
The finding that Mnt selectively interacts with mSin3 during cell cycle progression prompted us to investigate whether this interaction correlated with the expression of Myc target genes. We first analysed the expression of several Myc target gene-encoded proteins upon re-entry of quiescent fibroblasts into the cell cycle. As expected, cyclin D2, cyclin E, and cyclin-dependent kinase 4 (cdk4) were all induced upon serum stimulation (Figure 4a ). Interestingly, we found that cyclin D2 was transiently downregulated at 15 h after serum addition.
Next, we analysed the in vivo binding of Mnt and mSin3 proteins to the cyclin D2 promoter during cell cycle progression using chromatin immunoprecipitation (ChIP) assays. We found that Mnt was present at the cyclin D2 promoter throughout the cell cycle (Figure 4b ). In contrast, mSin3B binding was strongest in quiescent cells and at 15 h after serum stimulation, when the majority of the cells have passed S phase. This binding coincided with the decrease in cyclin D2 protein expression observed at 15 h (Figure 4a and b) . Histones H3 and H4 were deacetylated at the cyclin D2 promoter in quiescent cells. Acetylated histones could be detected at the promoter 5 h post serum addition and their levels remained unchanged at later time points (Figure 4b ). Provided that cyclin D2 is repressed through histone deacetylation after S phase, it is possible that the mSin3 interaction at 15 h results in deacetylation of histones at specific lysine residues. The antibodies used in our ChIP experiments may still recognize histones acetylated at certain residues even if they have been deacetylated at others.
To test the possibility that Mnt recruited mSin3 to the cyclin D2 promoter in quiescent cells but not after serum stimulation, we performed sequential ChIPs from starved and serum-stimulated NIH3T3 cells. After crosslinking, protein-DNA complexes were precipitated with a-Mnt antibody, eluted from the antibodysepharose complexes, and a second immunoprecipitation using a-mSin3 antibody was performed. As shown in Figure 4c , Mnt was present at the cyclin D2 promoter both in quiescent cells and after serum stimulation. In contrast, the Mnt-mSin3 complex could only be detected at the cyclin D2 promoter in growth-arrested cells. These observations support our co-immunprecipitation assays (Figure 3b ) and suggest that Mnt-mediated recruitment of mSin3-HDAC complexes contributes to the repression of cyclin D2 in quiescent cells.
Interference with Mnt expression results in upregulation of cyclin D2 expression in quiescent NIH3T3 fibroblasts
Our data demonstrated that Mnt binds and recruits mSin3 to the cyclin D2 promoter in quiescent cells (Figure 4b and c) . To verify that Mnt is required for repression of cyclin D2 in growth-arrested fibroblasts, we transfected NIH3T3 cells with a plasmid expressing Mnt-targeting siRNA. After transfection, the cells were growth-arrested by serum depletion and analysed for Mnt and cyclin D2 expression. As shown in Figure 4d , cyclin D2 was upregulated in a dose-dependent manner in correlation with decreased Mnt expression. Other Mnt target gene-encoded proteins, cyclin E and cdk4, were also upregulated in a similar manner (Figure 4d ). These data suggest that cyclin D2 is a target gene for both Myc and Mnt proteins, and that Mnt is likely to be a critical mediator of the cyclin D2 repression in quiescent cells.
In control experiments, we performed ChIP analysis on the cyclin D2 promoter in NIH3T3 and Mnt-null cells. As expected, we observed binding of Mnt to the cyclin D2 promoter in NIH3T3 but not in MntÀ/À cells (Figure 4e) . Similarly, mSin3B was present at the promoter in NIH3T3 cells but almost undetectable in Figure 3 The interaction between Mnt and mSin3 is inhibited at re-entry into the cell cycle. Extracts from logarithmically growing NIH3T3 were used to perform immunoprecipiations (IP) with normal rabbit IgG, Mnt, mSin3B, and HDAC1 followed by Western blot (WB) analysis for mSin3B (a). Mnt was immunoprecipitated from quiescent and serum-stimulated NIH3T3 cells and analysed for the presence of mSin3A, mSin3B, and Mnt by Western blotting (b, upper panel) . The total amount of mSin3 proteins in the extracts was detected by Western blotting (b, lower panel). Whole-cell extracts from U0126-treated, serum-stimulated (5 h) NIH3T3 cells in parallel with untreated extracts from quiescent (0 h) and serum-stimulated (5 h) cells were used for IP with a-Mnt antibody. Precipitates were analysed by Western blotting with mSin3B and Mnt antibodies (c, upper and middle panels). The level of mSin3B in total extracts was analysed by Western blotting (c, lower panel) Figure 4 Mnt-mSin3 binding to the cyclin D2 promoter and upregulation of cyclin D2 upon interference with Mnt expression. Whole-cell extracts from NIH3T3 cells were collected every 5 h post serum stimulation of quiescent cells and analysed for Myc, cyclin D2, cdk4, cyclin E, and b-actin by Western blotting (WB) (a). Chromatin immunoprecipitation (ChIP) analysis of binding of Mnt and mSin3B and histone H3 and H4 acetylation at the cyclin D2 promoter during cell cycle progression in NIH3T3 cells (b). Sequential ChIP assay using Mnt and mSin3B antibodies in quiescent (0 h) and serum-stimulated (5 h) NIH3T3 fibroblasts (c). Logarithmically growing NIH3T3 cells were transfected with either pSUPER vector control or Mnt-targeting pSUPER-Mnt siRNA-25 plasmids, followed by serum withdrawal and selection for puromycin resistance for 24 h. Whole-cell extracts were analysed for expression of Mnt, cyclin D2, cdk4, and cyclin E by Western blotting 48 h post-transfection. b-Actin was used to ensure equal protein loading (d). The binding of Mnt and mSin3B to the cyclin D2 promoter in NIH3T3 (3T3) and Mnt-null (À/À) cells was analysed by ChIP (e). The ChIP assays shown are representative from at least two independent experiments Mnt is regulated during cell cycle progression N Popov et al Mnt À/À cells (Figure 4e ). These data support the notion that Mnt recruits mSin3B to the cyclin D2 promoter.
Mnt interacts with mSin3 and binds to the cyclin D2 promoter in quiescent HL60 cells
We then examined whether the Mnt-mSin3 interaction also is regulated in another cell type. Promyelocytic leukemia HL60 cells downregulate Myc and upregulate Mad1 concomitantly with growth arrest upon dimethyl sulfoxide (DMSO)-induced differentiation (Larsson et al., 1994; Xu et al., 2001) . We analysed Mnt expression and its ability to recruit mSin3 in these cells and found that Mnt was expressed both before and after DMSO treatment. As expected, Myc was sharply downregulated upon cell cycle arrest (Figure 5a and b). Similar to our observations in NIH3T3 fibroblasts, we found that Mnt was present predominantly in its faster migrating form in quiescent HL60 cells and treatment with phosphatase showed that the 74 kDa protein represented the hyperphosphorylated protein (Figure 5a and c) . Furthermore, in vivo phosphate labeling demonstrated a significantly reduced level of Mnt phosphorylation in DMSO-treated compared to proliferating cells (Figure 5c ).
Next, we analysed the Mnt-mSin3 interaction and found that the ability of Mnt to associate with mSin3B increased upon DMSO treatment of HL60 cells (Figure 5d ). The interaction was strongest in growtharrested cells when Mnt was present predominantly in the hypophosphorylated form (Figure 5c and d) . Taken together, these observations indicate that the ability of Mnt to bind mSin3 proteins is regulated at the transition from proliferation to quiescence.
As cyclin D2 has been shown to be downregulated during DMSO treatment of HL60 cells (Bouchard et al., 2001) , we analysed binding of Mnt and Max to the cyclin D2 promoter in these cells. Both Mnt and Max bound to the promoter before and after differentiation (Figure 5e ). In agreement with previous observations, Myc was present at the cyclin D2 promoter in logarithmically growing cells and was replaced by Mad1 after DMSO treatment (Bouchard et al., 2001 ). Acetylation of histones H3 and H4 correlated to Myc binding and practically no acetylated histones were detected at the promoter after differentiation (Figure 5e ). The finding that both Mnt and Mad1 associated with the cyclin D2 promoter in quiescent HL60 cells together with our observation that Mnt associated more efficiently with mSin3 upon DMSO treatment suggests that both Mnt and Mad1 proteins contributed to the change in acetylation status ( Figure 5e ) and in turn, to cyclin D2 repression.
The Mnt associated HDAC activity is decreased upon serum stimulation
Since our data suggested that the faster migrating form of Mnt predominantly interacts with mSin3, we performed mSin3 immunoprecipitations and analysed the Mnt pattern. For this experiment, we used an mSin3A antibody directed against the amino-terminal region of mSin3A, since the mSin3B antibody is directed against the PAH2 region, which mediates interaction with Mnt. Our data demonstrated that mainly the faster migrating form of Mnt was present in the mSin3A immunoprecipitate, although both Mnt proteins were expressed in extracts from logarithmically growing NIH3T3 cells (Figure 6a ). This indicates that the hypophosphorylated Mnt protein is the predominant interaction partner of mSin3. As a control we performed the same experiment in immortalized Mnt À/À cells. Similar amounts of mSin3A were precipitated in both NIH3T3 and Mnt À/À cells; however as expected, Mnt was only present in the precipitates from NIH3T3 cells ( Figure 6a ). As mSin3 proteins in turn recruit HDACs, we next analysed the presence of HDAC1 and mSin3 proteins in Mnt immunoprecipitates in NIH3T3 and immortalized Mnt-null cells. We found that Mnt recruited mSin3A and mSin3B in NIH3T3 cells, whereas mSin3 proteins were not detected in immunoprecipitates using the Mnt antibody in Mnt À/À cells (Figure 6b) . Similarly, we observed HDAC1 in Mnt immunoprecipitates from NIH3T3 but not from Mnt À/À cells. In contrast, mSin3A and mSin3B immunoprecipitates contained HDAC1 in both cell lines. As seen in Figure 6b , the mSin3A antibody showed crossreactivity with the mSin3B protein and vice versa. Figure 6 Recruitment of HDAC protein and activity by Mnt in quiescent cells. mSin3A was immunoprecipitated (IP) from logarithmically growing NIH3T3 (3T3) and Mnt-null (À/À) cells followed by Western blot (WB) analysis for mSin3A and Mnt. In parallel, total cell extracts from logarithmically growing cells were used for mSin3A and Mnt expression by WB (a). Extracts from logarithmically growing NIH3T3 and Mnt-null cells were used for immunoprecipiations (IP) with normal rabbit IgG, Mnt, mSin3A, and mSin3B antibodies followed by WB analysis for mSin3A, mSin3B, and HDAC1 (b). Mnt was immunoprecipitated from quiescent (0 h) and serum-stimulated (5 h) NIH3T3 cells followed by Western blot analysis for Mnt and HDAC1 expression. The total amount of Mnt and HDAC1 proteins in the extracts was detected by Western blotting (c). Histone deacetylase activity assay was performed in extracts from quiescent (0 h) and serum stimulated (5 h) NIH3T3 (3T3) and Mnt-null (À/À) cells after low stringent a-Mnt immunoprecipitations (d) and in total cell extracts (e). The data presented in (d) and (e) is the mean of three independent experiments in duplicate with standard deviation
In view of the fact that we had observed HDAC1 in Mnt immunoprecipitates and demonstrated that Mnt interacted efficiently with mSin3 proteins in quiescent cells, we analysed the recruitment of HDAC1 protein and activity by Mnt in resting and serum-stimulated cells. As shown in Figure 6c , we observed interaction of HDAC1 with Mnt in quiescent but not in cells induced to re-enter into the cell cycle. In parallel, we performed HDAC enzymatic measurements and observed that the Mnt-associated HDAC activity was reduced by approximately 50% in serum-stimulated compared to quiescent cells ( Figure 6d ). As expected, neither HDAC1 protein nor activity was detected in Mnt immunoprecipitates in MntÀ/À cells (Figure 6b and d) . To exclude that the observed decrease was due to a reduction in the total HDAC activity upon re-entry into the cell cycle, we performed assays in total cell extracts from NIH3T3 and Mnt-null cells. As shown in Figure 6e , the total HDAC activity was higher in NIH3T3 than in Mnt-null cells, but there was no change in the activity between quiescent or serum-stimulated cells in either cell type. In summary, our data indicate that HDAC1 protein and activity is more efficiently recruited by Mnt in quiescent compared to in growing cells.
Discussion
In this study we show that Mnt is phosphorylated upon entry of quiescent NIH3T3 fibroblasts into the cell cycle. Conversely, Mnt is dephosphorylated when logarithmically growing HL60 cells are treated with DMSO, which induces differentiation in parallel with growth arrest. We observed that Mnt recruited mSin3 in quiescent NIH3T3 fibroblasts. At 5 and 10 h after serum induction, when Mnt was mostly present in the hyperphosphorylated form, the interaction was nearly undetectable. Similarly, we found that Mnt precipitated more of mSin3 concomitantly with the disappearance of the hyperphosphorylated form of the protein during DMSO-induced differentiation of HL60 cells. These observations suggest a correlation between the phosphorylation status of Mnt and its ability to interact with mSin3. In support, we demonstrated that mainly the faster, 72 kDa hypophosphorylated form of Mnt was present in mSin3 immunoprecipitates. Taken together, these data indicate that the hypophosphorylated Mnt protein mediates mSin3 interaction and recruitment of HDAC activity.
We observed that phosphorylation of Mnt was induced already 10 min after serum addition to quiescent fibroblasts. Moreover, the phorbol ester TPA very efficiently induced Mnt phosphorylation in both resting and proliferating rodent fibroblasts as well as in human neuroblastoma cells (Grynfeld Smith et al. 2004 and data not shown). In addition, we found that treatment of cells with the MKK/ERK signal transduction pathway inhibitor U0126 prevented Mnt phosphorylation after serum stimulation and restored the Mnt-mSin3 interaction. This suggests that kinases of the MKK/ ERK signal transduction pathway are candidates for phosphorylation of Mnt. Interestingly, phosphorylation of the SP1-like TIEG2 repressor and the AML1 transcriptional regulator by activation of the ERK signaling pathway have been shown to disrupt their interaction with mSin3A (Ellenrieder et al., 2002; Imai et al., 2004) .
As shown in EMSA, we did not observe any direct correlation between the phosphorylation status of Mnt and the DNA-binding activity of the Mnt/Max heterodimer, but dephosphorylation of the cell extract induced a mobility shift of the Mnt/Max complex. However, since Max is also a phosphoprotein (Berberich and Cole, 1992; Bousset et al., 1993) , this could be due to dephosphorylation of either Mnt or Max, or of both proteins. Notably, we observed a considerable mobility shift of the Max/Max complex upon phosphatase treatment, suggesting that dephosphorylation of Max might cause the change in Mnt/Max mobility (Berberich and Cole, 1992) . In addition, our chromatin immunoprecipitation data suggest that Mnt binds to the consensus E-Box in the cyclin D2 promoter throughout the cell cycle, and thus, independently of its phosphorylation status.
We also analysed the consequences of Mnt binding and recruitment of the mSin3 cofactor to the cyclin D2 promoter during cell cycle progression. In quiescent cells, Mnt recruited mSin3 to the promoter, whereas the Mnt-mSin3 interaction was disrupted, concomitant with histone H3 and H4 acetylation, after serum stimulation. Later in the cell cycle, mSin3 was present at the cyclin D2 promoter again, which may account, at least in part, for the transient downregulation of cyclin D2. Moreover, introduction of Mnt-targeting siRNA into NIH3T3 cells resulted in upregulation of cyclin D2 during growth arrest, suggesting that Mnt plays an important role in repressing cyclin D2 transcription. Similarly, downregulation of Mnt by siRNA resulted in induction of cdk4 and cyclin E in quiescent cells. These two proteins have previously been shown to be upregulated in Mnt null mouse embryo fibroblasts (MEFs), and thus represent potential Mnt target genes (Hurlin et al., 2003) . In contrast, the cyclin D2 levels were shown to be unaffected in Mnt-null primary fibroblasts. This discrepancy may be due to differences associated with acute versus chronic loss of Mnt. Compensatory changes have been observed in several different knockout models such as in the retinoblastoma susceptibility gene (Rb)-null fibroblasts, where increased levels of the Rb-related p107 protein prevents quiescent Rb-null fibroblasts from entering the cell cycle, whereas cells from the conditional Rb knockout continue to cycle (Sage et al., 2003) . Similar compensatory changes, which would decrease the effects of Mnt loss during embryonic development in the Mnt À/À fibroblasts, could be changes in the expression of Mad, Mga, or Myc genes . We reproducibly observed in vivo association of Mnt with the cyclin D2 promoter in both fibroblasts and leukemia cells indicating that cyclin D2 is a relevant target of Mnt. In quiescent/differentiated HL60 cells, Mnt efficiently interacted with mSin3 and bound to the cyclin D2 promoter. It is therefore conceivable that Mnt contributes to cyclin D2 repression in concert with Mad1, which previously has been shown to repress cyclin D2 in differentiated HL60 cells (Bouchard et al., 2001) .
The ability of Mnt to repress transcription depends on its association with mSin3 proteins, which in turn recruit histone deacetylases and corepressor molecules to target promoters. We have demonstrated that the ability of Mnt to bind mSin3 is decreased when quiescent mouse fibroblasts re-enter the cell cycle and is enhanced during DMSO-induced cell cycle arrest of HL60 cells. Earlier reports have demonstrated that Mnt interacts with mSin3 (Hurlin et al., 1997a; Meroni et al., 1997) . However, in these studies, in vitro translated or recombinant proteins were used to analyse the interaction. Our data, together with data published by Walker et al. while this manuscript was under revision, show the first evidence of Mnt-mSin3 interaction under physiological conditions when neither of the proteins has been overexpressed. In addition, we demonstrated that the Mnt-associated HDAC activity was reduced upon serum stimulation. Disruption of the Mnt-mSin3 interaction with a lower HDAC activity as a consequence might be essential for proper induction of Myc target genes during G1 to S transition. We suggest a model where proliferation-stimulatory signals, such as growth factors present in serum, induce hyperphosphorylation of Mnt and disruption of the Mnt-mSin3 interaction and HDAC recruitment. Release of mSin3 would allow Myc to activate transcription of genes required for G1 to S phase transition. After the onset of S phase, the hypophosphorylated form of Mnt may be responsible for repressing target genes whose protein products are no longer required for the cell cycle progression. Thus, two mechanisms may act in concert to ensure Myc-dependent gene activation after serum stimulation of quiescent cells. Namely, modulation of Mnt-dependent repression caused by changes in the ability of Mnt to bind mSin3 as demonstrated in this study as well as an increase in the ratio between c-Myc/ Max and Mnt/Max caused by the strongly induced Myc levels after serum stimulation (Walker et al., 2005) .
Despite the fact that Mnt is located in the 17p13.3 region, which is associated with loss of heterozygosity in human tumors, neither mutations nor deletions of the other allele have been found (Nigro et al., 1998; Takahashi et al., 1998; Sommer et al., 1999) . However, it was recently shown that the expression of Mnt was reduced in six out of 14 medulloblastoma tumors analysed and Mnt was therefore suggested to be a potential tumor suppressor (Cvekl et al., 2004) . This notion is supported by the findings that Mnt loss mimics Myc overexpression and confers apparent tumorigenic advantage in Mnt-null MEFs and in cells with downregulated Mnt expression (Hurlin et al., 2003; . It will be interesting to see whether disruption of the Mnt-mSin3 interaction and thus loss of Mnt-mediated repression is a common mechanism in cancer development.
Materials and methods
Cell culture
NIH3T3 (3T3) cells were cultured in Iscove's modified Eagle's medium (IMDM) supplemented with 10% fetal bovine serum (FBS), penicillin (10 U/ml), and streptomycin (10 U/ml). Immortalized Mnt-null mouse fibroblasts (À/À) and TGR-1 rat fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma) containing FBS, penicillin, and streptomycin. Cells were starved in medium containing 0.1% FBS for 48 h before serum stimulation and samples were collected every 5 h during 25 h for cell cycle experiments. Human promyelocytic leukemia HL60 cells were cultured in RPMI-1680 medium supplemented with 10% FBS, penicillin, and streptomycin. For differentiation, cells were treated with 1.5% DMSO for 48 h (Xu et al., 2001) .
Antibodies
The following antibodies were used: a-acetylated histone H3 (06-599) and a-acetylated histone H4 (06-866) from Upstate; -20) , normal rabbit IgG, a-rabbit, and a-mouse HRPconjugated antibodies, all from Santa Cruz; a-b-actin (Sigma), and a rabbit polyclonal against Mnt (a kind gift from RN Eisenman).
DNA profile analysis
For PI staining of DNA, cells were collected at appropriate time points, washed with PBS, and fixed overnight with 70% ethanol. Fixed cells were incubated with 25 mg/ml PI and 1000 Kunitz units/ml RNAse A for 1 h. Samples were analysed on Becton Dickinson FACScan system using CellQuest and Modfit software.
EMSA
Whole-cell extracts were prepared in nondenaturing lysis buffer (NLB), containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF, and 2 mg/ ml leupeptin. Binding reactions were performed in 10 mM TrisHCl pH 7.5, 100 mM KCl, 5 mM MgCl 2 , and 1 mM DTT, with 5 mg whole-cell extract, 0.01 mg/ml sonicated salmon sperm DNA, and 1 ng of end-labeled oligonucleotide, 5 0 -TCAGAC-CACGTGGTCGGG-3 0 . For antibody supershifts, Max, Mnt, or USF antibodies were added to the binding reaction and incubated for 10 min at room temperature prior to the addition of the labeled probe. The samples were incubated at 101C for 30 min and separated on 5% acrylamide gels in 0.25 Â TBE buffer (25 mM Tris, 25 mM Boric acid, and 0.5 mM EDTA) for 4 h at 400 V. The gels were dried and DNA-protein complexes were visualized with Phosphor Imager technology (Molecular Dynamics).
Phosphatase treatment
Whole-cell extracts were incubated with 500 U of recombinant lPPase (New England BioLabs) in the presence of 2 mM MnCl 2 in 1 Â lPPase buffer (NEB) for 30 min at 301C. Where indicated 10 mM Na 3 VO 4 was included in the reaction to inhibit phosphatase activity. Treated extracts were used for EMSA or Western blotting.
Immunoprecipitation and Western blot analysis
Whole-cell extracts were prepared either in LS buffer (20 mM HEPES pH 7.5, 100 mM KCl, 10 mM MgCl 2 , 1 mM dithiothreniol (DTT), 0.2% NP-40) or NLB buffer supplemented with protease inhibitors. Extracts were incubated with the indicated antibodies for 2 h at 41C and the antigen-antibody complexes were collected with protein A-sepharose (Amersham) for 1 h at 41C. Protein complexes were washed three times with LS buffer or immunoprecipitaion (IP) wash buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100), once with PBS, and proteins were separated by SDS-polyacrylamide gels. Western blotting was performed as described previously (Bejarano et al., 2000) . For experiments with the MKK/ERK signaling transduction inhibitor U0126 (Cell Signaling Technology), serum-starved NIH3T3 cells were pretreated with 10 or 20 mM of U0126 in DMSO or the vehicle alone for 30 min before serum stimulation.
In vivo phosphate labeling NIH3T3 or HL60 cells (3 Â 10 6 ) were incubated for 2 h with 0.2 mCi orthophosphate (Amersham) in sodium phosphatefree DMEM supplemented with either 0.1 or 10% FBS, previously dialysed against 0.85% sodium chloride. Cells were lysed in RIPA buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, supplemented with protease inhibitors), and immunoprecipitations were performed for 2 h at 41C with the indicated antibodies. The antigen-antibody complexes were collected with protein A-sepharose (Amersham) for 1 h at 41C. Proteins were separated on 8% SDS-polyacrylamide gels. The gels were dried and labeled proteins were visualized using Phosphor Imager.
ChIP assays
For HL60 cells, ChIP assays were performed as described previously (Xu et al., 2001) . For NIH3T3 and Mnt À/À cells, 2 Â 10 6 cells were crosslinked with formaldehyde to a final concentration of 1% for 10 min at 371C. The cells were pelleted and lysed in ChIP lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 0.5% SDS) supplemented with protease inhibitors. Lysates were sonicated, diluted in modified RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate), and used for immunopreciptations at 41C over night. Samples for total chromatin (input) were taken at this point to use as positive controls in the PCR. Antibodyprotein-DNA complexes were collected with protein A sepharose beads for 1 h at 41C followed by three washes with modified RIPA buffer and once with PBS. Immunoprecipitates were eluted twice for 10 min at 651C with elution buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 1% SDS) followed by reverse crosslinking with 250 mM NaCl at 651C over night. Proteins were digested by Proteinase K and the DNA was purified using phenol/chloroform extraction and precipitated with ethanol and glycogen (Invitrogen) as a carrier at À201C over night. DNA fragments were recovered by centrifugation and washed once with ethanol before resuspended in 10 mM Tris-HCl pH 8.0. Primer sequences, for PCR-amplification of the region containing E-Box in the murine or human cyclin D2 promoter, are available upon request. The PCR products were fractionated on 2% agarose gels stained with ethidium bromide. For sequential ChIP assays, DNA-protein complexes from the first immunoprecipitation were eluted with 1% SDS and 10 mM DTT for 30 min at 371C, diluted 1 : 20 in NLB buffer and used for the second immunoprecipitation (Shang et al., 2000) .
RNA interference
For Mnt downregulation, siRNA oligos directed against Mnt mRNA were generated using Ambion guidelines (http:// www.ambion.com). The Mnt-targeting siRNA oligo 25 (sequences available upon request) was inserted into the pSUPER vector and cotransfected together with pBabe-puro using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. In brief, NIH3T3 cells were seeded in IMDM medium without antibiotics the day before transfection. The DNA and Lipofectamine 2000 were diluted and combined in serum-free IMDM medium, incubated for 20 min and added to the cells. At 24 h post-transfection, cells were starved and selected for puromycin resistance by changing to IMDM containing 0.25% and 5 mg/ml puromycin. At 48 h after transfection, cells were harvested for Western blot analysis.
HDAC assay
Histone deacetylase activity was detected either in total cell extracts or after low stringency immunoprecipitation using Mnt antibodies. The protein complexes were washed once with LS buffer without DTT, once with LS buffer without NP-40 and DTT, and finally once with HDAC assay buffer (Upstate) before analysis of HDAC activity using the Upstate fluorimetric detection HDAC assay kit according to the manufacturer's instructions. In brief, immunoprecipitates were incubated with HDAC assay substrate (Upstate) for 1 h at 301C. Activator solution (Upstate) was added and samples were incubated at RT for 10 min. Excitation (350-380 nm) and emission (440-460 nm) were measured using a SpectraMAX Gemini XS (Molecular Devices).
